BeiGene, Ltd. (BGNE)
NASDAQ: BGNE · Real-Time Price · USD
207.25
+3.04 (1.49%)
Nov 4, 2024, 4:00 PM EST - Market closed
BeiGene Employees
BeiGene had 10,600 employees as of December 31, 2023. The number of employees increased by 1,400 or 15.22% compared to the previous year.
Employees
10,600
Change (1Y)
1,400
Growth (1Y)
15.22%
Revenue / Employee
$292,126
Profits / Employee
-$49,405
Market Cap
22.02B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 10,600 | 1,400 | 15.22% |
Dec 31, 2022 | 9,200 | 1,000 | 12.20% |
Dec 31, 2021 | 8,200 | 2,900 | 54.72% |
Dec 31, 2020 | 5,300 | 1,941 | 57.79% |
Dec 31, 2019 | 3,359 | 1,289 | 62.27% |
Dec 31, 2018 | 2,070 | 1,170 | 130.00% |
Dec 31, 2017 | 900 | 552 | 158.62% |
Dec 31, 2016 | 348 | 108 | 45.00% |
Dec 31, 2015 | 240 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Koninklijke Philips | 69,656 |
Teva Pharmaceutical | 37,851 |
STERIS | 18,179 |
Zimmer Biomet Holdings | 18,000 |
The Cooper Companies | 15,000 |
Illumina | 13,360 |
West Pharmaceutical Services | 10,600 |
Waters | 7,900 |
BGNE News
- 7 days ago - BeiGene Mourns Death of Beloved Board Member Donald Glazer - Business Wire
- 14 days ago - BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma - Business Wire
- 19 days ago - BeiGene Highlights Waldenström's Macroglobulinemia Innovation at IWWM 2024 - Business Wire
- 4 weeks ago - Chinese Biopharmaceutical Stocks Surge with Positive Policy Impact - GuruFocus
- 5 weeks ago - BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers - Business Wire
- 5 weeks ago - Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors - Business Wire
- 6 weeks ago - BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy - Business Wire
- 2 months ago - Phonak + Advanced Bionics sponsor new family film, Rally Caps - Worldwide release on September 10th - Business Wire